Email page PDF view Print view Email Alert Social Media Sharing

Repligen to Present at Baird’s 2017 Global Healthcare Conference

Company Release - 8/30/2017 3:20 PM ET

WALTHAM, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will present at Baird’s 2017 Healthcare Conference in New York on Wednesday, September 6, at 9:05 a.m. EDT.

A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and filtration products (including XCell™ ATF systems, TangenX™ Sius™ flat sheet TFF cassettes and hardware, and Spectrum KrosFlo™ hollow fiber TFF cartridges and systems). The Protein A ligands and growth factors that we produce are key components of affinity resins and cell culture media, respectively. Protein A affinity resins are the industry standard for downstream purification of monoclonal antibody-based therapeutics. Growth factors are used in upstream processes to accelerate cell growth and productivity. Our line of OPUS® chromatography columns, used in downstream processes for bench- through clinical-scale purification, are uniquely customizable to our customers’ choice of resin and packed bed height. Our innovative XCell™ ATF systems, available in stainless steel and single-use configurations, continuously eliminate waste from a bioreactor to concentrate cells and significantly increase productivity in upstream processes. Single-use Sius™ TFF cassettes and hardware are used for biologic drug concentration in downstream filtration processes. Spectrum KrosFlo™ TFF cartridges and systems are used in both upstream and downstream processes. Repligen’s corporate headquarters are in Waltham, MA (USA), with additional administrative and manufacturing operations in Shrewsbury, MA, Rancho Dominguez, CA, Lund, Sweden and Weingarten, Germany.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Repligen Contact:
Sondra S. Newman
Senior Director Investor Relations
(781) 419-1881
investors@repligen.com

Primary Logo

Source: Repligen Corporation